Skip to main content
Top

25-04-2024 | Fluticasone | Review Article

Intraclass comparison of inhaled corticosteroids for the risk of pneumonia in chronic obstructive pulmonary airway disorder: a network meta-analysis and meta-regression

Authors: Kannan Sridharan, Gowri Sivaramakrishnan

Published in: International Journal of Clinical Pharmacy

Login to get access

Abstract

Background

Inhalational corticosteroids (ICS) were observed to increase the pneumonia risk in chronic obstructive pulmonary airway disorder (COPD). However, it is unknown whether any differences exist between the drugs within the ICS class.

Aim

This study aimed to evaluate the risk of pneumonia associated with different ICS and identify factors that predict pneumonia in patients with moderate-to-severe COPD using a network meta-analysis.

Method

Electronic databases (Medline, Cochrane CENTRAL and Google Scholar) were searched for trials comparing ICS in COPD patients. The outcomes were pneumonia and serious pneumonia. Odds ratios (OR) with 95% confidence interval (95% CI) were estimated. Meta-regression was used to identify the predictors. The strength of evidence was graded using the Grading of Recommendations, Assessment, Development, and Evaluations approach.

Results

Sixty-six studies (103,347 participants) were included. Fluticasone (OR: 1.46; 95% CI: 1.26, 1.7), mometasone (OR: 2.2; 95% CI: 1.05, 4.6), and beclometasone (OR: 1.7; 95% CI: 1.1, 2.6) were observed with an increased pneumonia risk compared to placebo. Fluticasone (OR: 1.5; 95% CI: 1.3, 1.7) was observed with an increased risk of serious pneumonia. High doses (OR: 1.2; 95% CI: 1.03, 1.4), BMI ≥ 25 kg/m2 (OR: 1.6; 95% CI: 1.1, 2.2), and history of exacerbations in the preceding year predicted the pneumonia risk. Evidence strength was moderate.

Conclusion

ICS class differences in pneumonia risk were observed in terms of pooled effect estimates but it is unlikely that any clinically relevant differences exist. Risk–benefit analysis supports ICS use in moderate-severe COPD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Park SC, Kim DW, Park EC, et al. Mortality of patients with chronic obstructive pulmonary disease: a nationwide population based cohort study. Korean J Intern Med. 2019;34(6):1272–8.PubMedPubMedCentralCrossRef Park SC, Kim DW, Park EC, et al. Mortality of patients with chronic obstructive pulmonary disease: a nationwide population based cohort study. Korean J Intern Med. 2019;34(6):1272–8.PubMedPubMedCentralCrossRef
3.
go back to reference Miravitlles M, Roman-Rodríguez M, Ribera X, et al. Inhaled corticosteroid use among COPD patients in primary care in Spain. Int J Chronic Obstr Pulm Dis. 2022;17:245–58.CrossRef Miravitlles M, Roman-Rodríguez M, Ribera X, et al. Inhaled corticosteroid use among COPD patients in primary care in Spain. Int J Chronic Obstr Pulm Dis. 2022;17:245–58.CrossRef
7.
go back to reference Calverley P. Reigniting the TORCH: chronic obstructive pulmonary disease mortality and inhaled corticosteroids revisited. Am J Respir Crit Care Med. 2021;203(5):531–2.PubMedPubMedCentralCrossRef Calverley P. Reigniting the TORCH: chronic obstructive pulmonary disease mortality and inhaled corticosteroids revisited. Am J Respir Crit Care Med. 2021;203(5):531–2.PubMedPubMedCentralCrossRef
8.
go back to reference Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax. 2013;68(6):499–500.PubMedCrossRef Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax. 2013;68(6):499–500.PubMedCrossRef
10.
go back to reference Mkorombindo T, Dransfield MT. Inhaled corticosteroids in chronic obstructive pulmonary disease: benefits and risks. Clin Chest Med. 2020;41(3):475–84.PubMedPubMedCentralCrossRef Mkorombindo T, Dransfield MT. Inhaled corticosteroids in chronic obstructive pulmonary disease: benefits and risks. Clin Chest Med. 2020;41(3):475–84.PubMedPubMedCentralCrossRef
11.
go back to reference Zhang Q, Li S, Zhou W, et al. Risk of pneumonia with different inhaled corticosteroids in COPD patients: a meta-analysis. COPD. 2020;17(4):462–9.PubMedCrossRef Zhang Q, Li S, Zhou W, et al. Risk of pneumonia with different inhaled corticosteroids in COPD patients: a meta-analysis. COPD. 2020;17(4):462–9.PubMedCrossRef
12.
go back to reference Yang M, Du Y, Chen H, et al. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;77: 105950.PubMedCrossRef Yang M, Du Y, Chen H, et al. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;77: 105950.PubMedCrossRef
13.
go back to reference Suissa S. Inhaled corticosteroids and pneumonia mortality in COPD patients. Eur Respir J. 2019;54(3):1901276.PubMedCrossRef Suissa S. Inhaled corticosteroids and pneumonia mortality in COPD patients. Eur Respir J. 2019;54(3):1901276.PubMedCrossRef
14.
go back to reference Chen H, Sun J, Huang Q, et al. Inhaled corticosteroids and the pneumonia risk in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12: 691621.PubMedPubMedCentralCrossRef Chen H, Sun J, Huang Q, et al. Inhaled corticosteroids and the pneumonia risk in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12: 691621.PubMedPubMedCentralCrossRef
15.
go back to reference Lodise TP, Li J, Gandhi HN, et al. Intraclass difference in pneumonia risk with fluticasone and budesonide in COPD: a systematic review of evidence from direct-comparison studies. Int J Chronic Obstr Pulm Dis. 2020;15:2889–900.CrossRef Lodise TP, Li J, Gandhi HN, et al. Intraclass difference in pneumonia risk with fluticasone and budesonide in COPD: a systematic review of evidence from direct-comparison studies. Int J Chronic Obstr Pulm Dis. 2020;15:2889–900.CrossRef
16.
go back to reference Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906–16.PubMedPubMedCentralCrossRef Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906–16.PubMedPubMedCentralCrossRef
18.
go back to reference Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.PubMedCrossRef Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.PubMedCrossRef
19.
go back to reference Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
20.
go back to reference Gjerdevik M, Heuch I. Improving the error rates of the Begg and Mazumdar test for publication bias in fixed effects meta-analysis. BMC Med Res Methodol. 2014;14:109.PubMedPubMedCentralCrossRef Gjerdevik M, Heuch I. Improving the error rates of the Begg and Mazumdar test for publication bias in fixed effects meta-analysis. BMC Med Res Methodol. 2014;14:109.PubMedPubMedCentralCrossRef
26.
go back to reference Wallace BC, Lajeunesse MJ, Schmid CH, et al. OpenMEE: Intuitive, open-source software for meta-analysis in ecology and evolutionary biology. Methods Ecol Evol. 2017;8(8):941–7.CrossRef Wallace BC, Lajeunesse MJ, Schmid CH, et al. OpenMEE: Intuitive, open-source software for meta-analysis in ecology and evolutionary biology. Methods Ecol Evol. 2017;8(8):941–7.CrossRef
27.
28.
go back to reference Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone–salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med. 2007;146:45-55. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone–salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med. 2007;146:45-55.
29.
go back to reference Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD J Chronic Obstr Pulm Dis. 2009;6(5):320–9. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD J Chronic Obstr Pulm Dis. 2009;6(5):320–9.
30.
go back to reference Bansal S, Anderson M, Anzueto A, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. Prim Care Respir Med. 2021;31(1):29.PubMedPubMedCentralCrossRef Bansal S, Anderson M, Anzueto A, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. Prim Care Respir Med. 2021;31(1):29.PubMedPubMedCentralCrossRef
31.
go back to reference Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int J Chronic Obstr Pulm Dis. 2016;4(11):193–205.CrossRef Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int J Chronic Obstr Pulm Dis. 2016;4(11):193–205.CrossRef
32.
go back to reference Beeh KM, Kuna P, Corradi M, et al. Comparison of Dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium in patients with COPD: the TRI-D randomized controlled trial. COPD. 2021;16:79–89.CrossRef Beeh KM, Kuna P, Corradi M, et al. Comparison of Dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium in patients with COPD: the TRI-D randomized controlled trial. COPD. 2021;16:79–89.CrossRef
33.
go back to reference Betsuyaku T, Kato M, Fujimoto K, et al. A randomized trial of symptom-based management in Japanese patients with COPD. COPD. 2018;13:2409–23.CrossRef Betsuyaku T, Kato M, Fujimoto K, et al. A randomized trial of symptom-based management in Japanese patients with COPD. COPD. 2018;13:2409–23.CrossRef
34.
go back to reference Bhatt S, Dransfield M, Cockcroft J, et al. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD. COPD. 2017;12:351–65.CrossRef Bhatt S, Dransfield M, Cockcroft J, et al. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD. COPD. 2017;12:351–65.CrossRef
35.
go back to reference Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–303.PubMedPubMedCentralCrossRef Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–303.PubMedPubMedCentralCrossRef
36.
go back to reference Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–9.PubMedCrossRef Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–9.PubMedCrossRef
37.
go back to reference Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9(1):73.PubMedPubMedCentralCrossRef Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9(1):73.PubMedPubMedCentralCrossRef
38.
go back to reference Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.PubMedCrossRef Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.PubMedCrossRef
39.
go back to reference Calverley PMA, Kuna P, Monsó E, et al. Beclomethasone/formoterol in the management of COPD: A randomised controlled trial. Respir Med. 2010;104(12):1858–68.PubMedCrossRef Calverley PMA, Kuna P, Monsó E, et al. Beclomethasone/formoterol in the management of COPD: A randomised controlled trial. Respir Med. 2010;104(12):1858–68.PubMedCrossRef
40.
go back to reference Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–39.PubMedCrossRef Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–39.PubMedCrossRef
41.
go back to reference Cheng SL, Su KC, Wang HC, et al. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Des. 2014:601-7. Cheng SL, Su KC, Wang HC, et al. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Des. 2014:601-7.
42.
go back to reference Covelli H, Pek B, Schenkenberger I, et al. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. COPD. 2015;1. Covelli H, Pek B, Schenkenberger I, et al. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. COPD. 2015;1.
43.
go back to reference Doherty D, Tashkin D, Kerwin, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. COPD. 2012;57. Doherty D, Tashkin D, Kerwin, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. COPD. 2012;57.
44.
go back to reference Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–81.PubMedCrossRef Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–81.PubMedCrossRef
45.
go back to reference Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–23.PubMedCrossRef Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–23.PubMedCrossRef
46.
go back to reference Dransfield MT, Cockcroft JR, Townsend RR, et al. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med. 2011;105(9):1322–30.PubMedCrossRef Dransfield MT, Cockcroft JR, Townsend RR, et al. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med. 2011;105(9):1322–30.PubMedCrossRef
47.
go back to reference Dransfield MT, Crim C, Criner GJ, et al. Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Annals ATS. 2021;18(5):788–98.CrossRef Dransfield MT, Crim C, Criner GJ, et al. Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Annals ATS. 2021;18(5):788–98.CrossRef
48.
go back to reference Fatima S, Tariq F, Saqib Ur Rehman M, et al. Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease. PJMHS. 2023;17(4):12–6. Fatima S, Tariq F, Saqib Ur Rehman M, et al. Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease. PJMHS. 2023;17(4):12–6.
49.
go back to reference Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med. 2008;102(8):1099–108.PubMedCrossRef Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med. 2008;102(8):1099–108.PubMedCrossRef
50.
go back to reference Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131.PubMedPubMedCentralCrossRef Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131.PubMedPubMedCentralCrossRef
51.
go back to reference Ferguson GT, Papi A, Anzueto A, et al. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. Eur Respir J. 2018;52(3):1801334.PubMedPubMedCentralCrossRef Ferguson GT, Papi A, Anzueto A, et al. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. Eur Respir J. 2018;52(3):1801334.PubMedPubMedCentralCrossRef
52.
go back to reference Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–58.PubMedCrossRef Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–58.PubMedCrossRef
53.
go back to reference Ferguson GT, Tashkin DP, Skärby T, et al. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir Med. 2017;132:31–41.PubMedCrossRef Ferguson GT, Tashkin DP, Skärby T, et al. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir Med. 2017;132:31–41.PubMedCrossRef
54.
go back to reference Frith PA, Ashmawi S, Krishnamurthy S, et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology. 2018;23(12):1152–9.PubMedCrossRef Frith PA, Ashmawi S, Krishnamurthy S, et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology. 2018;23(12):1152–9.PubMedCrossRef
55.
go back to reference Fukuchi Y, Samoro R, Fassakhov R, et al. Budesonide/formoterol via Turbuhaler® versus formoterol via T urbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results. Respirology. 2013;18(5):866–73.PubMedCrossRef Fukuchi Y, Samoro R, Fassakhov R, et al. Budesonide/formoterol via Turbuhaler® versus formoterol via T urbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results. Respirology. 2013;18(5):866–73.PubMedCrossRef
56.
go back to reference Hanania NA, Crater GD, Morris AN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1):91–101.PubMedCrossRef Hanania NA, Crater GD, Morris AN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1):91–101.PubMedCrossRef
57.
go back to reference Hanania NA, Papi A, Anzueto A, et al. Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. ERJ Open Res. 2020;6(2):00187–2019.PubMedPubMedCentralCrossRef Hanania NA, Papi A, Anzueto A, et al. Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. ERJ Open Res. 2020;6(2):00187–2019.PubMedPubMedCentralCrossRef
58.
go back to reference Huang K, Guo Y, Kang J, et al. The efficacy of adding budesonide/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China. Ther Adv Respir Dis. 2019;13:175346661985350.CrossRef Huang K, Guo Y, Kang J, et al. The efficacy of adding budesonide/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China. Ther Adv Respir Dis. 2019;13:175346661985350.CrossRef
59.
go back to reference Ichinose M, Fukushima Y, Inoue Y, et al. Long-term safety and efficacy of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD. COPD. 2019;14:2993–3002.CrossRef Ichinose M, Fukushima Y, Inoue Y, et al. Long-term safety and efficacy of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD. COPD. 2019;14:2993–3002.CrossRef
60.
go back to reference Jung KS, Park HY, Park SY et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir med. 2012;106:382-9. Jung KS, Park HY, Park SY et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir med. 2012;106:382-9.
61.
go back to reference Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(2):144–9.PubMedCrossRef Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(2):144–9.PubMedCrossRef
62.
go back to reference Kerwin EM, Ferguson GT, Mo M, et al. Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. Respir Res. 2019;20(1):167.PubMedPubMedCentralCrossRef Kerwin EM, Ferguson GT, Mo M, et al. Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. Respir Res. 2019;20(1):167.PubMedPubMedCentralCrossRef
63.
go back to reference Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med. 2013;107(4):560–9.PubMedCrossRef Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med. 2013;107(4):560–9.PubMedCrossRef
64.
go back to reference Lee S, Xie C, Yunus F, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East Asia. Respirology. 2016;21(1):119–27.PubMedCrossRef Lee S, Xie C, Yunus F, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East Asia. Respirology. 2016;21(1):119–27.PubMedCrossRef
65.
go back to reference Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–80.PubMedCrossRef Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–80.PubMedCrossRef
66.
go back to reference Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–94.PubMedCrossRef Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–94.PubMedCrossRef
67.
go back to reference Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med. 2013;107(4):550–9.PubMedCrossRef Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med. 2013;107(4):550–9.PubMedCrossRef
68.
go back to reference Muiser S, Imkamp K, Seigers D, et al. Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. Thorax. 2023;78(5):451–8.PubMedCrossRef Muiser S, Imkamp K, Seigers D, et al. Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. Thorax. 2023;78(5):451–8.PubMedCrossRef
69.
go back to reference Ohar JA, Crater GD, Emmett A, et al. Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation. Respir Res. 2014;15(1):105.PubMedPubMedCentralCrossRef Ohar JA, Crater GD, Emmett A, et al. Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation. Respir Res. 2014;15(1):105.PubMedPubMedCentralCrossRef
70.
go back to reference Panettieri RA Jr, Camargo CA Jr, Cheema T, et al. Effect of recent exacerbation history on the efficacy of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol triple therapy in patients with chronic obstructive pulmonary disease in the FULFIL trial. Int J Chronic Obstr Pulm Dis. 2022;1(17):2043–52.CrossRef Panettieri RA Jr, Camargo CA Jr, Cheema T, et al. Effect of recent exacerbation history on the efficacy of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol triple therapy in patients with chronic obstructive pulmonary disease in the FULFIL trial. Int J Chronic Obstr Pulm Dis. 2022;1(17):2043–52.CrossRef
71.
go back to reference Papi A, Dokic D, Tzimas W, et al. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. COPD. 2017;12:1961–71.CrossRef Papi A, Dokic D, Tzimas W, et al. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. COPD. 2017;12:1961–71.CrossRef
72.
go back to reference Pepin JL, Cockcroft JR, Midwinter D, et al. Long-acting bronchodilators and arterial stiffness in patients with COPD. Chest. 2014;146(6):1521–30.PubMedCrossRef Pepin JL, Cockcroft JR, Midwinter D, et al. Long-acting bronchodilators and arterial stiffness in patients with COPD. Chest. 2014;146(6):1521–30.PubMedCrossRef
73.
go back to reference Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.PubMedCrossRef Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.PubMedCrossRef
74.
go back to reference Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–65.PubMedPubMedCentralCrossRef Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–65.PubMedPubMedCentralCrossRef
75.
go back to reference Rossi A, Wehbe L, Quinn M, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44:1548-56. Rossi A, Wehbe L, Quinn M, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44:1548-56.
76.
go back to reference Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106(2):257–68.PubMedCrossRef Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106(2):257–68.PubMedCrossRef
77.
go back to reference Siler TM, Nagai A, Scott-Wilson CA, et al. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respir Med. 2017;123:8–17.PubMedCrossRef Siler TM, Nagai A, Scott-Wilson CA, et al. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respir Med. 2017;123:8–17.PubMedCrossRef
78.
go back to reference Singh D, Worsley S, Zhu CQ, et al. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;15(1):91.PubMedPubMedCentralCrossRef Singh D, Worsley S, Zhu CQ, et al. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;15(1):91.PubMedPubMedCentralCrossRef
79.
go back to reference Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975–2000.PubMedCrossRef Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975–2000.PubMedCrossRef
80.
go back to reference Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. Int J Chronic Obstr Pulm Dis. 2012;7:43–55. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. Int J Chronic Obstr Pulm Dis. 2012;7:43–55.
81.
go back to reference Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet. 2016;387(10030):1817–26.CrossRef Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet. 2016;387(10030):1817–26.CrossRef
82.
go back to reference Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–60.PubMedCrossRef Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–60.PubMedCrossRef
83.
go back to reference Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. The Lancet. 2017;389(10082):1919–29.CrossRef Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. The Lancet. 2017;389(10082):1919–29.CrossRef
84.
go back to reference Vestbo J, Søorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. The Lancet. 1999;353(9167):1819–23.CrossRef Vestbo J, Søorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. The Lancet. 1999;353(9167):1819–23.CrossRef
85.
go back to reference Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48(4):1030–9.PubMedCrossRef Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48(4):1030–9.PubMedCrossRef
86.
go back to reference Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.PubMedCrossRef Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.PubMedCrossRef
87.
go back to reference Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34.PubMedCrossRef Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34.PubMedCrossRef
88.
go back to reference Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.PubMedCrossRef Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.PubMedCrossRef
89.
go back to reference Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108(8):1153–62.PubMedCrossRef Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108(8):1153–62.PubMedCrossRef
90.
go back to reference Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741–50.PubMedCrossRef Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741–50.PubMedCrossRef
91.
go back to reference Zheng J, Baldi S, Zhao L, et al. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. Respir Res. 2021;22(1):90.PubMedPubMedCentralCrossRef Zheng J, Baldi S, Zhao L, et al. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. Respir Res. 2021;22(1):90.PubMedPubMedCentralCrossRef
92.
go back to reference Zheng J, De Guia T, Wang-Jairaj J, et al. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Curr Med Res Opin. 2015;31(6):1191–200.PubMedCrossRef Zheng J, De Guia T, Wang-Jairaj J, et al. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Curr Med Res Opin. 2015;31(6):1191–200.PubMedCrossRef
93.
go back to reference Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. COPD. 2015;10:1015–26. Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. COPD. 2015;10:1015–26.
95.
go back to reference Choi JH, Jeong KB, Park YH, et al. Comparison of risk of pneumonia caused by fluticasone propionate versus budesonide in chronic obstructive pulmonary disease: a nationwide retrospective cohort study. Int J Chronic Obstr Pulm Dis. 2021;16:3229–37.CrossRef Choi JH, Jeong KB, Park YH, et al. Comparison of risk of pneumonia caused by fluticasone propionate versus budesonide in chronic obstructive pulmonary disease: a nationwide retrospective cohort study. Int J Chronic Obstr Pulm Dis. 2021;16:3229–37.CrossRef
96.
go back to reference Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346: f3306.PubMedPubMedCentralCrossRef Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346: f3306.PubMedPubMedCentralCrossRef
97.
go back to reference Maassen van den Brink KI, Boorsma M, Staal-van den Brekel AJ, et al. Evidence of the in vivo esterification of budesonide in human airways. Br J Clin Pharmacol. 2008;66(1):27–35. Maassen van den Brink KI, Boorsma M, Staal-van den Brekel AJ, et al. Evidence of the in vivo esterification of budesonide in human airways. Br J Clin Pharmacol. 2008;66(1):27–35.
98.
go back to reference Dalby C, Polanowski T, Larsson T, et al. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10(1):104.PubMedPubMedCentralCrossRef Dalby C, Polanowski T, Larsson T, et al. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10(1):104.PubMedPubMedCentralCrossRef
99.
go back to reference Yebyo HG, Braun J, Menges D, et al. Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit-harm modelling study. Lancet Digit Health. 2021;3(10):e644–53.PubMedCrossRef Yebyo HG, Braun J, Menges D, et al. Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit-harm modelling study. Lancet Digit Health. 2021;3(10):e644–53.PubMedCrossRef
100.
101.
go back to reference Kim RY, Glick C, Furmanek S, et al. Association between body mass index and mortality in hospitalised patients with community-acquired pneumonia. ERJ Open Res. 2021;7(1):00736–2020.PubMedPubMedCentralCrossRef Kim RY, Glick C, Furmanek S, et al. Association between body mass index and mortality in hospitalised patients with community-acquired pneumonia. ERJ Open Res. 2021;7(1):00736–2020.PubMedPubMedCentralCrossRef
Metadata
Title
Intraclass comparison of inhaled corticosteroids for the risk of pneumonia in chronic obstructive pulmonary airway disorder: a network meta-analysis and meta-regression
Authors
Kannan Sridharan
Gowri Sivaramakrishnan
Publication date
25-04-2024
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-024-01736-8
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare